According to a research conducted in the United Kingdom, the herpes simplex virus was utilised to reduce and eradicate cancerous tumours,
the BBC reported on September 23. The medication is an altered, weaker version of the cold sore virus that kills tumours.
Directly administered injections into tumours infiltrate malignant cells, causing them to explode.
The immune system is also stimulated by the injections.
In the trial, there were about 40 patients.
In spite of moderate side effects including weariness, ten out of thirty individuals experienced some benefits from the treatment.
The so-called RP2 virus injection is not the first cold-virus-based treatment.
The National Health Service approved T-Vec for use in advanced skin cancer several years ago.